← All companies
REPLIGEN CORP
RGEN - CIK 0000730272
Market cap$7.38 B
Rank#1116
SEC filings1,331
REPLIGEN CORP trades as RGEN and has a market capitalization of $7.38 B, making it the #1116 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $738.26M, up 16.4% from the prior year and net income of $48.89M. This page tracks REPLIGEN CORP through 1,331 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$738.26MFY 2025
Net income (latest FY)$48.89MFY 2025
Operating cash flow (latest FY)$117.42MFY 2025
Total assets (latest FY)$2.95BFY 2025
Net margin6.6%latest FY
Financial performance
Over the last 9 fiscal years REPLIGEN CORP's revenue grew from $104.54M to $738.26M, a compound annual growth rate of 24.3%. Net profit margin compressed from 11.2% to 6.6% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $7.38 B
- Share price (derived)market cap / shares outstanding
- $130.76
- P/E ratio (trailing FY)
- 150.9
- EPS (diluted)FY 2025
- $0.86
- Shares outstandingas of 2026-05-01
- 0.06B
- Total equityas of 2026-03-31
- $2.11B
- Return on equity
- 2.3%
- Long-term debtas of 2026-03-31
- $546.59M
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
| Insider trade | 4 | 2026-05-18 |
Recent press releases
- Repligen Reports First Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance2026-04-22
_First quarter revenue of $194 million, a year-over-year increase of 15% as reported and 11% organic_
- Repligen to Report First Quarter 2026 Financial Results2026-04-22
The conference call will be accessible by dialing toll-free (833) 461-5787 for domestic callers and (585) 542-9983 for international callers. The meeting ID is: 931163466. In addition, a webcast will be accessible via the Investor Relations section of the Company’s website. The webcast will be archived for a period of time following the live event. You can access the replay on the Investor Relations section of the Company’s website.
- Repligen Opens European Training & Innovation Center in Breda, Expanding Global Customer Support Network2026-04-17
The Breda RTIC is Repligen’s third global training and innovation center, joining existing locations in Waltham, Massachusetts and Tokyo, Japan. The Breda opening event, held on April 15th, welcomed key biopharma and CDMO customers and highlighted Repligen’s continued investment in customer proximity and global support capabilities.
- Repligen Corporation to Present at Upcoming March Conferences2026-03-05
A live webcast of the Leerink and KeyBanc presentations will be accessible through Repligen’s Investor Relations website at www.repligen.com, and will be available for replay for a limited period of time following the events.
Similar companies
The largest companies sharing REPLIGEN CORP's SEC industry classification (biological products, (no diagnostic substances)).
Frequently asked questions
What is REPLIGEN CORP's market cap?
REPLIGEN CORP (RGEN) has a market capitalization of $7.38 B as of 2026-06-11, ranking #1116 among US-listed companies.
How much revenue does REPLIGEN CORP make?
REPLIGEN CORP reported revenue of $738.26M for fiscal year 2025, an increase of 16.4% year over year.
Is REPLIGEN CORP profitable?
Yes. REPLIGEN CORP reported net income of $48.89M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.